Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
View through CrossRef
Poly (ADP-ribose) polymerase (PARP) 1 is an essential molecule in DNA damage response by sensing DNA damage and docking DNA repair proteins on the damaged DNA site through a type of posttranslational modification, poly (ADP-Ribosyl)ation (PARylation). PARP inhibitors, which inhibit PARylation through competitively binding to NAD+ binding site of PARP1 and PARP2, have improved clinical benefits for BRCA mutated tumors, leading to their accelerated clinical application. However, the antitumor activities of PARP inhibitors in clinical development are different, due to PARP trapping activity beyond blocking PARylation reactions. In this review, we comprehensively address the current state of knowledge regarding the mechanisms of action of PARP inhibitors. We will also discuss the different effects of PARP inhibitors in combination with cytotoxic chemotherapeutic agents regarding the mechanism of regulating PARylation.
Title: PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
Description:
Poly (ADP-ribose) polymerase (PARP) 1 is an essential molecule in DNA damage response by sensing DNA damage and docking DNA repair proteins on the damaged DNA site through a type of posttranslational modification, poly (ADP-Ribosyl)ation (PARylation).
PARP inhibitors, which inhibit PARylation through competitively binding to NAD+ binding site of PARP1 and PARP2, have improved clinical benefits for BRCA mutated tumors, leading to their accelerated clinical application.
However, the antitumor activities of PARP inhibitors in clinical development are different, due to PARP trapping activity beyond blocking PARylation reactions.
In this review, we comprehensively address the current state of knowledge regarding the mechanisms of action of PARP inhibitors.
We will also discuss the different effects of PARP inhibitors in combination with cytotoxic chemotherapeutic agents regarding the mechanism of regulating PARylation.
Related Results
Abstract 1718: Schlafen 11 (SLFN11) is a critical determinant of cellular sensitivity to PARP inhibitors
Abstract 1718: Schlafen 11 (SLFN11) is a critical determinant of cellular sensitivity to PARP inhibitors
Abstract
Poly(ADP-ribose)polymerases (PARP) are DNA damage sensors and major repair factors for DNA single-strand breaks. Since the discovery of the synthetic lethal...
Abstract PR-10: PARP inhibition induces genomic instability in normal human cells.
Abstract PR-10: PARP inhibition induces genomic instability in normal human cells.
Abstract
Recent research has focused on poly(ADP-ribose) polymerases (PARPs) as potential chemotherapeutic targets. Tumors which harbor defects in DNA double-strand ...
Abstract 363: CYT01B, a novel RAD51 inhibitor, acts synergistically with PARP inhibitors
Abstract 363: CYT01B, a novel RAD51 inhibitor, acts synergistically with PARP inhibitors
Abstract
Genomic instability is recognized as a driver of tumorigenesis and cancer progression. Loss of tumor suppressors or activation of oncogenes can induce DN...
Abstract B063: Interplay between PARP and the RB/E2F axis in prostate cancer
Abstract B063: Interplay between PARP and the RB/E2F axis in prostate cancer
Abstract
Retinoblastoma (RB) protein is a tumor suppressor that represses the transcriptional activity of E2Fs by forming an RB-E2F repressor complex. The phosphoryl...
PARylation-mediated post-transcriptional modifications in cancer immunity and immunotherapy
PARylation-mediated post-transcriptional modifications in cancer immunity and immunotherapy
Poly-ADP-ribosylation (PARylation) is a post-translational modification in which ADP-ribose is added to substrate proteins. PARylation is mediated by a superfamily of ADP-ribosyl t...
PARP inhibitors in melanoma treatment: potential, challenges, and future directions
PARP inhibitors in melanoma treatment: potential, challenges, and future directions
Genome integrity is a critical driver of cellular stability, and defects in the processes that maintain genome health are potent sources of cancer progression. Homologous recombina...
PARP Inhibition as a Treatment Modality in Melanoma: What We Have Learned and What We Hope to Achieve
PARP Inhibition as a Treatment Modality in Melanoma: What We Have Learned and What We Hope to Achieve
Genome integrity is a critical driver of cellular stability, and defects in the processes that maintain genome health are potent sources of cancer progression. Homologous recombina...
Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases
Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases
Over the past decade, Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors have arisen as a novel and promising targeted therapy for breast cancer gene (BRCA)-mutated ovarian and bre...